Degradation strategy of cyclin D1 in cancer cells and the potential clinical application

Shuyi Chen; Ling Li

doi:10.3389/fonc.2022.949688

Degradation strategy of cyclin D1 in cancer cells and the potential clinical application

Front Oncol. 2022 Aug 18:12:949688. doi: 10.3389/fonc.2022.949688. eCollection 2022.

Authors

Shuyi Chen¹, Ling Li²

Affiliations

¹ The Sixth Student Battalion, School of Basic Medical Sciences, Fourth Military Medical University, Xi'an, China.
² Department of Cell Biology, National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China.

Abstract

Cyclin D1 has been reported to be upregulated in several solid and hematologic tumors, promoting cancer progression. Thus, decreasing cyclin D1 by degradation could be a promising target strategy for cancer therapy. This mini review summarizes the roles of cyclin D1 in tumorigenesis and progression and its degradation strategies. Besides, we proposed an exploration of the degradation of cyclin D1 by FBX4, an F box protein belonging to the E3 ligase SKP-CUL-F-box (SCF) complex, which mediates substrate ubiquitination, as well as a postulate about the concrete combination mode of FBX4 and cyclin D1. Furthermore, we proposed a possible photodynamic therapy strategythat is based on the above concrete combination mode for treating superficial cancer.

Keywords: FBX4; cancer cells; combination mode; cyclin D1 degradation; photodynamic therapy.

Publication types

Review